

## テーマA: 「増殖シグナルを標的とした革新的がん治療法探索・開発」

- 1) Tsutsui N., Tanabe G., Morita N., Okayama Y., Kita A., Sugiura R., Muraoka O.: Structure-activity relationship studies on acremomannolipin A, the potent calcium signal modulator with a novel glycolipid structure 3: Role of the length of alditol side chain. *Bioorg Med Chem*, 23(13): 3761-3773 (2015)
- 2) Kita A., Higa M., Doi A., Satoh R., Sugiura R.: Imp2, the PSTPIP homolog in fission yeast, affects sensitivity to the immunosuppressant FK506 and membrane trafficking in fission yeast. *Biochem Biophys Res Commun*, 457(3): 273-279 (2015)
- 3) Higa M., Kita A., Hagihara K., Kitai Y., Doi A., Nagasoko R., Satoh R., Sugiura R.: Spatial control of calcineurin in response to heat shock in fission yeast. *Genes Cells*, 20(2): 95-107 (2015)
- 4) 佐藤亮介, 萩原加奈子, 喜多綾子, 杉浦麗子: カルシニューリンの新たな制御機構と医療・創薬への応用—RNA 顆粒によるカルシニューリンの空間的制御—. *生化学* 87(5): 517-524 (2015)
- 5) \* Nakanishi I., Murata K., Nagata N., Kurono M., Kinoshita T., Yasue M., Miyazaki T., Takei Y., Nakamura S., Sakurai A., Iwamoto N., Nishiwaki K., Nakaniwa T., Sekiguchi Y., Hirasawa A., Tsujimoto G., Kitaura K.: Identification of Protein Kinase CK2 Inhibitors using Solvent Dipole Ordering Virtual Screening. *Eur. J. Med. Chem.* 96, 396–404.(2015) 査読有り
- 6) Kawashita N., Yamasaki H., Miyao T., Kawai K., Sakae Y., Ishikawa T., Mori K., Nakamura S., Kaneko H.: A Mini-review on Chemoinformatics Approaches for Drug Discovery. *J. Comput. Aided Chem.* 16, 15–29.(2015) 査読有り
- 7) Ogata F., Ueta E., Kawasaki N.: Adsorption capability of ionic dyes onto pristine and calcined activated clay, *e-J. Surf. Sci. Nanotech.* 14, 209-215 (2016) 査読有り
- 8) Ogata F., Kawasaki N.: Regeneration of waste edible oil by the use of virgin and calcined magnesium hydroxide as adsorbents, *J. Oleo Sci.* 65(11), 941-948 (2016) 査読有り
- 9) Ogata F., Kawasaki N.: Adsorption capability of calcined gibbsite for V, Sr, and Mo from a complex solution system, *J. Water Environ. Technol.* 14(5), 362-371 (2016) 査読有り
- 10) Ogata F., Ueda A., Tanei S., Imai D., Kawasaki N.: Simultaneous removal of phosphate and nitrite ions from aqueous solutions using modified soybean waste, *J. Ind. Eng. Chem.* 35, 287-294 (2016) 査読有り
- 11) Nagai N., Ogata F., Kawasaki N., Ito Y.: Increased expression of interleukin 18 in lenses of ovariectomized rat, *Biol. Pharm. Bull.* 39(1), 138-142 (2016) 査読有り
- 12) Ogata F., Imai D., Toda M., Otani M., Kawasaki N.: Properties of a novel adsorbent produced by calcination of nickel hydroxide and its capability for phosphate ion adsorption, *J. Ind. Eng. Chem.* 34, 172-179 (2016) 査読有り

- 13) Ogata F., Kawasaki N.: Adsorption of As(III) from aqueous solutions by novel Fe-Mg type hydrotalcite, *Chem. Pharm. Bull.* 63(12), 1040-1046 (2015) 査読有り
- 14) Ogata F., Iwata Y., Kawasaki N.: Kinetic and equilibrium investigation of cobalt(II), nickel(II), and tungsten(VI) adsorption on fly ash processed by hydrothermal treatment in an alkaline solution, *J. Water Environ. Technol.* 13(5), 359-370 (2015) 査読有り
- 15) Nagai N., Ogata F., Kawasaki N., Ito Y., Funakami Y., Okamoto N., Shimomura Y.: Hypercalcemia leads to delayed wound healing in ovariectomized rats, *Biol. Pharm. Bull.* 38(7), 1063-1069 (2015) 査読有り
- 16) Ogata F., Imai D., Toda M., Otani M., Kawasaki N.: Adsorption of phosphate ion in aqueous solutions by calcined cobalt hydroxide at different temperatures, *J. Environ. Chem. Eng.* 3, 1570-1577 (2015) 査読有り
- 17) Ogata F., Imai D., Kawasaki N.: Cationic dye removal from aqueous solution by waste biomass produced from calcination treatment of rice bran, *J. Environ. Chem. Eng.* 3, 1476-1485 (2015) 査読有り
- 18) Ogata F., Iwata Y., Kawasaki N.: Properties of novel adsorbent produced by hydrothermal treatment of waste fly ash in alkaline solution and its capability for adsorption of tungsten from aqueous solution, *J. Environ. Chem. Eng.* 3, 333-338 (2015) 査読有り
- 19) Ogata F., Imai D., Kawasaki N.: Adsorption of nitrate and nitrite ions onto carbonaceous material produced from soybean in a binary solution system, *J. Environ. Chem. Eng.* 3, 155-161(2015) 査読有り
- 20) \* Yuan Q., Furukawa T., Okita K., Jin ZH., Aung W., Sugyo A., Nagatsu K., Endo H., Tsuji AB., Zhang MR., Masuko T., Inoue M., Fujibayashi Y., Saga T.: Immuno-PET imaging of HER3 in a model in which HER3 signaling plays a critical role. *PLoS ONE* 10(11), e0143076. (2015)
- 21) Takechi M., Wada T., Yagi H., Masuko T., Kawabata A.: Oubain exert cytoprotection by diminishing the intracellular K (+) concentration increase caused by distinct stimuli in human leukemic cells. *J Pharm Pharmacol* 67(1), 126-32. (2015)
- 22) \* Morikawa T., Ninomiya K., Akaki J., Kakihara N., Kuramoto H., Matsumoto Y., Hayakawa T., Muraoka O., Wang L.-B., Wu L.-J., Nakamura S., Yoshikawa M., Matsuda H.: Dipeptidyl peptidase-IV inhibitory activity of dimeric dihydrochalcone glycosides from flowers of *Helichrysum arenarium*. *J. Nat. Med.* 69, 494-506 (2015) 査読有り **平成 28 年度 日本生薬学会論文賞 受賞、” Change the World, One Article at a Time: Must-Read Articles from 2015 (Springer 社)” に選出**
- 23) \* Tanabe G., Sugano Y., Shirato M., Sonoda N., Tsutsui N., Morikawa T., Ninomiya K., Yoshikawa M., Muraoka O.: Total Synthesis of 4,5-Didehydroguadiscine: A Potent Melanogenesis Inhibitor from the Brazilian Medicinal Herb, *Hornschurchia oblique*. *J. Nat. Prod.* 78, 1536-1542 (2015) 査読有り
- 24) \* Morikawa T., Ninomiya K., Takamori Y., Nishida E., Yasue M., Hayakawa T., Muraoka O., Li X., Nakamura S., Yoshikawa M., Matsuda H.: Oleanane-type triterpene saponins with collagen synthesis-promoting activity from the flowers of *Bellis perennis*. *Phytochemistry*, 116, 203-212 (2015) 査読有り

- 25) \* Inoue T., Matsui Y., Kikuchi T., Yamada T., In Y., Muraoka O., Sakai C., Ninomiya K., Morikawa T., Tanaka R.: Carapanolides M-S from seeds of andiroba (*Carapa guianensis*, Meliaceae) and triglyceride metabolism-promoting activity in high glucose-pretreated HepG2 cells. *Tetrahedron*, 71, 2753-2760 (2015) 査読有り
- 26) \* Morikawa T., Akaki J., Ninomiya K., Kinouchi E., Tanabe G., Pongpiriyadacha Y., Yoshikawa M., Muraoka O.: Salacinol and Related Analogs: New Leads for Type 2 Diabetes Therapeutic Candidates from the Thai Traditional Natural Medicine *Salacia chinensis*. *Nutrients*, 7, 1480-1493 (2015) 査読有り
- 27) \* Sakamoto A., Tanaka Y., Yamada T., Kikuchi T., Muraoka O., Ninomiya K., Morikawa T., Tanaka R.: Andirolides W-Y from the flower oil of andiroba (*Carapa guianensis*, Meliaceae). *Fitoterapia* 100, 81-87 (2015) 査読有り
- 28) Hamamoto H., Umemoto H., Umemoto M., Ohta C., Fujita E., Nakamura A., Maegawa T., Miki Y.: Decarboxylative Halogenation of Indolecarboxylic Acids Using Hypervalent Iodine(III) Reagent and Its Application to the Synthesis of Polybromoindoles. *Heterocycle*. 91, 561-572 (2015)
- 29) Tsubaki M., Takeda T., Kino T., Itoh T., Imano M., Tanabe G., Muraoka O., Satou T., Nishida S.: Mangiferin suppresses CIA by suppressing the expression of TNF- $\alpha$ , IL-6, IL-1 $\beta$ , and RANKL through inhibiting the activation of NF- $\kappa$ B and ERK1/2. *Am J Transl Res.*, 7, 1371-1381 (2015) 査読有り
- 30) Yamamoto S., Iwata T., Nishiwaki K., Kinoshita M., Suzuki S.: Synthesis of quaternary ammonium derivatives of cellulose as the coating reagents for capillary electrophoresis. *Chromatography*, 2015, 36, 93-98(2015) 査読有り
- 31) Yamamoto S., Tamata Y., Sejima K., Kinoshita M., Suzuki S.: Chiral separation of D/L-aldoses by micellar electrokinetic chromatography using a chiral derivatization reagent and a phenylboronic acid complex. *Anal. Bioanal. Chem.* 407, 6201-6206 (2015) 査読有り
- 32) Yamamoto S., Nagai E., Asada Y., Kinoshita M., Suzuki S.: A rapid and highly sensitive microchip electrophoresis of mono- and mucin-type oligosaccharides labeled with 7-amino-4-methylcoumarin. *Anal. Bioanal. Chem.*, 407, 1409-1503 (2015) 査読有り
- 33) \* Yamamoto T., Uemura K., Moriyama K., Mitamura K., Taga A.: Inhibitory effect of maple syrup on cell growth and invasion of human colorectal cancer cells. *Oncol Rep.* 33,1579-1584 (2015) 査読有り

#### テーマB: 「癌・増殖シグナル制御メカニズム解析」

- 1) Doi A., Fujimoto A., Sato S., Uno T., Kanda Y., Asami K., Tanaka Y., Kita A., Satoh R., Sugiura R.: A chemical genomics approach to identify genes associated with sensitivity to rapamycin in the fission yeast *Scizosaccharomyces pombe*. *Genes Cells*, 20(4): 292-309 (2015)
- 2) Doi A., Kita A., Kanda Y., Uno T., Asami K., Satoh R., Nakano K., Sugiura R.: The geranylgeranyltransferase Cwg2-Rho4/Rho5 module is implicated in the Pmk1 MAPK Kinase-mediated cell wall integrity pathway in fission yeast. *Genes Cells*, 20(4): 310-323 (2015)

- 3) Yamamoto T., Uemura K., Sawashi Y., Mitamura K., Taga A.: Optimization of method to extract collagen from “Emperor” tissue of soft-shelled turtles. *J Oleo Sci.* 65, 169-175 (2016) 査読有り
- 4) \* Kawase A, Hata S, Takagi M, Iwaki M.: Pravastatin modulate niemann-pick C1-like 1 and ATP-binding cassette G5 and G8 to influence intestinal cholesterol absorption. *J Pharm Pharm Sci*, 18, 765-772 (2015). 査読有り
- 5) \* Kawase A, Ito A, Yamada A, Iwaki M.: Age-related changes in mRNA levels of hepatic transporters, cytochrome P450 and UDP-glucuronosyltransferase in female rats. *Eur J Drug Metabol Pharmacokinet*, 40, 239-244 (2015). 査読有り
- 6) Tsubaki M., Takeda T., Kino T., Obata N., Itoh T., Imano M., Mashimo K., Fujiwara D., Sakaguchi K., Satou T., Nishida S.: Statins improve survival by inhibiting spontaneous metastasis and tumor growth in a mouse melanoma model. *Am J Cancer Res.*, 5, 3186-3197 (2015) 査読有り
- 7) Peng YF., Imano M., Itoh T., Satoh T., Chiba Y., Imamoto H., Tsubaki M., Nishida S., Yasuda T., Furukawa H.: A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer. *J Surg Oncol.*, 111, 1041-1046 (2015) 査読有り
- 8) Tsubaki M., Takeda T., Tani T., Shimaoka H., Suzuyama N., Sakamoto K., Fujita A., Ogawa N., Itoh T., Imano M., Funakami Y., Ichida S., Satou T., Nishida S.: PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects. *Int J Cancer.*, 137, 243-250 (2015) 査読有り
- 9) Tsubaki M., Takeda T., Ogawa N., Sakamoto K., Shimaoka H., Fujita A., Itoh T., Imano M., Ishizaka T., Satou T., Nishida S.: Overexpression of survivin via activation of ERK1/2, Akt, and NF- $\kappa$ B plays a central role in vincristine resistance in multiple myeloma cells. *Leuk Res.*, 39, 445-452 (2015) 査読有り
- 10) Nagai N., Yoshioka C., Ito Y., Funakami Y., Nishikawa F., Kawabata A.: Intravenous administration of cilostazol nanoparticles ameliorates acute ischemic stroke in a cerebral ischemia/reperfusion-induced injury model. *Int. J. Mol. Sci.*, 16, 29329-29344 (2015). 査読有り
- 11) Fukami K., Sekiguchi F., Yasukawa M., Asano E., Kasamatsu R., Ueda M., Yoshida S., Kawabata A.: Functional upregulation of the H2S/Cav3.2 channel pathway accelerates secretory function in neuroendocrine-differentiated human prostate cancer cells. *Biochem. Pharmacol.* 97, 300-309 (2015). 査読有り
- 12) Fukami K., Kawabata A.: Hydrogen sulfide and neuronal differentiation: focus on Ca<sup>2+</sup> channels. *Nitric Oxide*, 46, 50-54 (2015). 査読有り
- 13) Murakami-Nakayama M., Tsubota M., Hiruma S., Sekiguchi F., Matsuyama K., Kimura T., Moriyama M., Kawabata A.: Polaprezinc attenuates cyclophosphamide-induced cystitis and related bladder pain in mice. *J. Pharmacol. Sci.*, 127, 223-28 (2015). 査読有り

- 14) Terada Y., Kawabata A.: H<sub>2</sub>S and pain: a novel aspect for processing of somatic, visceral and neuropathic pain signals. In *Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide*, edited by Moore P.K., Whiteman M., Springer, *Handb. Exp. Pharmacol.* 230: 217-230 (2015). 査読有り
- 15) Terada Y., Fujimura M., Nishimura S., Tsubota M., Sekiguchi F., Kawabata A.: Roles of Cav3.2 and TRPA1 channels targeted by hydrogen sulfide in pancreatic nociceptive processing in mice with or without acute pancreatitis. *J. Neurosci. Res.*, 93, 361-369 (2015). 査読有り
- 16) Maeda Y., Sekiguchi F., Yamanaka R., Sugimoto R., Yamasoba D., Tomita S., Nishikawa H., Kawabata A.: Mechanisms for proteinase-activated receptor 1-triggered prostaglandin E<sub>2</sub> generation in mouse osteoblastic MC3T3-E1 cells. *Biol. Chem.*, 396, 153-162 (2015). 査読有り
- 17) Hirobe S., Azukizawa H., Hanafusa T., Matsuo K., Quan YS., Kamiyama F., Katayama I., Okada N., Nakagawa S.: Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. *Biomaterials*, 57, 50-58 (2015) 査読有り
- 18) Wada A., Ito A., Iitsuka H., Tsuneyama K., Miyazono T., Murakami J., Shibahara N., Sakurai H., Saiki I., Nakayama T., Yoshie O., Koizumi K., Sugiyama T.: Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments. *Oncol. Rep.* 33, 2935-2939 (2015) 査読有り
- 19) Fox JC., Nakayama T., Tyler RC., Sander TL., Yoshie O., Volkman BF.: Structural and agonist properties of XCL2, the other member of the C-chemokine subfamily. *Cytokine*, 71, 302-11 (2015) 査読有り
- 20) Murata Y., Hori H., Taga A., Tada H.: Surface charge-transfer complex formation of catechol on titanium(IV) oxide and the application to bio-sensing. *J Colloid Interface Sci.* 458, 305-309 (2015) 査読有り
- 21) Arai K., Terashima H., Aizawa S., Taga A., Yamamoto A., Tsutsumiuchi K., Kodama S.: Simultaneous Determination of Trigonelline, Caffeine and Chlorogenic Acid in Instant Coffee by HPLC Using an Acidic Mobile Phase Containing Octanesulfonate. *Anal. Sci.* 31, 831-835 (2015) 査読有り
- 22) Mabuchi M., Shimizu T., Ueda M., Mitamura K., Ikegawa S., Tanaka A.: Improvement of solid material for affinity resins by application of long PEG spacers to capture the whole target complex of FK506. *Bioorg Med Chem Lett.* 25, 2788-2792 (2015) 査読有り
- 23) Shou M., Terashima H., Aizawa S., Taga A., Yamamoto A., Kodama S.: Simultaneous Enantioseparation of Aldoheoses and Aldopentoses Derivatized with L-Tryptophanamide by Reversed Phase HPLC Using Butylboronic Acid as a Complexation Reagent of Monosaccharides. *Chirality.* 27, 417-21 (2015) 査読有り
- 24) Takaya A., Peng WX., Ishino K., Kudo M., Yamamoto T., Wada R., Takeshita T., Naito Z.: Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma. *Int J Oncol.* 46,1573-1581 (2015) 査読有り
- 25) Nagai N., Yamamoto T., Tanabe W., Ito Y., Kurabuchi S., Mitamura K., Taga A.: Changes in plasma glucose in otuka long-evans tokushima fatty rats after oral administration of maple syrup. *J Oleo Sci.* 64, 331-335 (2015) 査読有り

- 26) Yoneshige A., Hagiyama M., Inoue T., Mimae T., Kato T., Okada M., Enoki E., Ito A.: Increased ectodomain shedding of cell adhesion molecule 1 as a cause of type II alveolar epithelial cell apoptosis in patients with idiopathic interstitial pneumonia. *Respir Res.* 16, 19 (2015). 査読有り
- 27) \* Hagiyama M., Yoneshige A., Inoue T., Sato Y., Mimae T., Okada M., Ito A.: The intracellular domain of cell adhesion molecule 1 is present in emphysematous lungs and induces lung epithelial cell apoptosis. *J Biomed Sci.* 22, 67. (2015). 査読有り
- 28) \* Mimae T., Ito A.: New challenges in pseudopodial proteomics by a laser-assisted cell etching technique. *Biochim Biophys Acta-Proteins Proteomics.* 1854, 538-546 (2015). 査読有り

#### テーマC: 「臨床評価・臨床腫瘍検体を用いた創薬シーズのPOC研究と個別化医療」

- 1) \* Yonesaka K., Kudo K., Nishida S., Takahama T., Iwasa T., Yoshida T., Tanaka K., Takeda M., Kaneda H., Okamoto I., Nishio K., Nakagawa K.: The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. *Oncotarget*, 6(32), 33602-11 (2015) 査読有り
- 2) \* Ishii H., Azuma K., Sakai K., Kawahara A., Yamada K., Tokito T., Okamoto I., Nishio K., Hoshino T.: Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. *Oncotarget*, 6(31), 30850-8 (2015) 査読有り
- 3) \* Satoh T., Lee KH., Rha SY., Sasaki Y., Park SH., Komatsu Y., Yasui H., Kim TY., Yamaguchi K., Fuse N., Yamada Y., Ura T., Kim SY., Munakata M., Saitoh S., Nishio K., Morita S., Yamamoto E., Zhang Q., Kim JM., Kim YH., Sakata Y.: Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. *Gastric Cancer*, 18(4), 824-32 (2015) 査読有り
- 4) \* Kimura M., Makio K., Hara K., Hiruma W., Fujita Y., Takata T., Nishio K., Ono N.: A Supramolecular Substance, [2] Rotaxane, Induces Apoptosis in Human Molt-3 Acute Lymphoblastic Leukemia Cells. *Drug Res (Stuttg)*, 65(11), 614-6 (2015) 査読有り
- 5) \* Sakiyama T., Tsurutani J., Iwasa T., Kawakami H., Nonagase Y., Yoshida T., Tanaka K., Fujisaka Y., Kurata T., Komoike Y., Nishio K., Nakagawa K.: A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer. *Br J Cancer*, 112(5), 819-24 (2015) 査読有り
- 6) \* Kogita A., Togashi Y., Hayashi H., Banno E., Terashima M., De Velasco MA., Sakai K., Fujita Y., Tomida S., Takeyama Y., Okuno K., Nakagawa K., Nishio K.: Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. *Int J Oncol*, 46(3), 1025-30 (2015) 査読有り
- 7) \* Yonesaka K., Satoh T., Ueda S., Yoshida T., Takeda M., Shimizu T., Okamoto I., Nishio K., Tamura T., Nakagawa K.: Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. *Anticancer Res*, 35(3), 1683-9 (2015) 査読有り

- 8) \* Yamaue H., Tsunoda T., Tani M., Miyazawa M., Yamao K., Mizuno N., Okusaka T., Ueno H., Boku N., Fukutomi A., Ishii H., Ohkawa S., Furukawa M., Maguchi H., Ikeda M., Togashi Y., Nishio K., Ohashi Y.: Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. *Cancer Sci*, 106(7), 883-90 (2015) 査読有り
- 9) \* Togashi Y., Kogita A., Sakamoto H., Hayashi H., Terashima M., De Velasco MA., Sakai K., Fujita Y., Tomida S., Kitano M., Okuno K., Kudo M., Nishio K.: Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. *Cancer Lett*, 356(2 Pt B), 819-27 (2015) 査読有り
- 10) \* Hayashi H., Arao T., Togashi Y., Kato H., Fujita Y., De Velasco MA., Kimura H., Matsumoto K., Tanaka K., Okamoto I., Ito A., Yamada Y., Nakagawa K., Nishio K.: The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. *Oncogene*, 34(2), 199-208 (2015) 査読有り
- 11) \* Sakai K., Takeda M., Okamoto I., Nakagawa K., Nishio K.: Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter. *Oncol Lett*, 9(1), 405-10 (2015) 査読有り
- 12) \* Togashi Y., Hayashi H., Terashima M., De Velasco MA., Sakai K., Fujita Y., Tomida S., Nakagawa K., Nishio K.: Inhibition of beta-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation. *J Thorac Oncol*, 10(1), 93-101 (2015) 査読有り
- 13) \* Kogita A., Yoshioka Y., Sakai K., Togashi Y., Sogabe S., Nakai T., Okuno K., Nishio K.: Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. *Biochem Biophys Res Commun*, 458(1), 52-6 (2015) 査読有り
- 14) \* Yoshioka Y., Togashi Y., Chikugo T., Kogita A., Taguri M., Terashima M., Mizukami T., Hayashi H., Sakai K., De Velasco MA., Tomida S., Fujita Y., Tokoro T., Ito A., Okuno K., Nishio K.: Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas. *Cancer*, 121(24), 4359-68 (2015) 査読有り
- 15) \* Kobayashi Y., Togashi Y., Yatabe Y., Mizuuchi H., Jangchul P., Kondo C., Shimoji M., Sato K., Suda K., Tomizawa K., Takemoto T., Hida T., Nishio K., Mitsudomi T.: EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. *Clin Cancer Res*, 21(23), 5305-13 (2015) 査読有り
- 16) \* Iwamoto Y., Mitsudomi T., Sakai K., Yamanaka T., Yoshioka H., Takahama M., Yoshimura M., Yoshino I., Takeda M., Sugawara S., Kawaguchi T., Takahashi T., Ohta M., Ichinose Y., Atagi S., Okada M., Saka H., Nakagawa K., Nakanishi Y., Nishio K.: Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-III Non-Small Cell Lung Cancer. *Clin Cancer Res*, 21(23), 5245-52 (2015) 査読有り
- 17) \* Togashi Y., Mizuuchi H., Tomida S., Terashima M., Hayashi H., Nishio K., Mitsudomi T.: MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. *Lung Cancer*, 90(3), 590-7 (2015) 査読有り

- 18) \* Sakai K., Takeda H., Nishijima N., Orito E., Joko K., Uchida Y., Izumi N., Nishio K., Osaki Y.: Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. *Oncotarget*, 6(25), 21636-44 (2015) 査読有り
- 19) \* Togashi Y., Mizuuchi H., Kobayashi Y., Hayashi H., Terashima M., Sakai K., Banno E., Mizukami T., Nakamura Y., De Velasco MA., Fujita Y., Tomida S., Mitsudomi T., Nishio K.: An activating ALK gene mutation in ALK IHC-positive/FISH-negative non-small-cell lung cancer. *Ann Oncol*, 26(8), 1800-1 (2015) 査読有り
- 20) \* Mizukami T., Togashi Y., Sogabe S., Banno E., Terashima M., De Velasco MA., Sakai K., Fujita Y., Tomida S., Nakajima TE., Boku N., Nishio K.: EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. *Int J Oncol*, 47(2), 499-505 (2015) 査読有り
- 21) \* Suzuki T., Ishibashi K., Yumoto A., Nishio K., Ogasawara Y.: Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells. *Oncol Lett*, 10(2), 805-09 (2015) 査読有り
- 22) \* Banno E., Togashi Y., Kobayashi Y., Hayashi H., Mitsudomi T., Nishio K.: Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion. *Anticancer Res*, 35(4), 2005-8 (2015) 査読有り
- 23) \* Yamaguchi T., Kurita T., Nishio K., Tsukada J., Hachisuga T., Morimoto Y., Iwai Y., Izumi H.: Expression of BAF57 in ovarian cancer cells and drug sensitivity. *Cancer Sci*, 106(4), 359-66 (2015) 査読有り
- 24) \* Togashi Y., Hayashi H., Okamoto K., Fumita S., Terashima M., De Velasco MA., Sakai K., Fujita Y., Tomida S., Nakagawa K., Nishio K.: Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. *Lung Cancer*, 88(1), 16-23 (2015) 査読有り
- 25) \* Sakai K., Yoneshige A., Ito A., Ueda Y., Kondo S., Nobumasa H., Fujita Y., Togashi Y., Terashima M., De Velasco MA., Tomida S., Nishio K.: Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. *Springerplus*, 4, 7 (2015) 査読有り
- 26) \* Koike H., Nozawa M., De Velasco MA., Kura Y., Ando N., Fukushima E., Yamamoto Y., Hatanaka Y., Yoshikawa K., Nishio K., Uemura H.: Conditional PTEN-deficient mice as a prostate cancer chemoprevention model. *Asian Pac J Cancer Prev*, 16(5), 1827-31 (2015) 査読有り
- 27) \* Nishio K., Mitsudomi T.: Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. *PLoS One*, 10(4), e0123901 (2015) 査読有り
- 28) \* Yamamoto Y., De Velasco MA., Kura Y., Nozawa M., Hatanaka Y., Oki T., Ozeki T., Shimizu N., Minami T., Yoshimura K., Yoshikawa K., Nishio K., Uemura H.: Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. *J Transl Med*, 13, 150 (2015) 査読有り
- 29) \* Sakai K., Tsurutani J., Yamanaka T., Yoneshige A., Ito A., Togashi Y., De Velasco MA., Terashima M., Fujita Y., Tomida S., Tamura T., Nakagawa K., Nishio K.: Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. *PLoS One*, 10(5), e0121891 (2015) 査読有り



- 30) \* Suda K., Murakami I., Sakai K., Mizuuchi H., Shimizu S., Sato K., Tomizawa K., Tomida S., Yatabe Y., Nishio K., Mitsudomi T.: Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. *Sci Rep*, 5, 14447 (2015) 査読有り
- 31) \* Yonesaka K., Takegawa N., Satoh T., Ueda H., Yoshida T., Takeda M., Shimizu T., Chiba Y., Okamoto I., Nishio K., Tamura T., Nakagawa K.: Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer. *PLoS One*, 10(11), e0143132 (2015) 査読有り
- 32) \* Tanaka Y., Aoyagi K., Minashi K., Komatsuzaki R., Komatsu M., Chiwaki F., Tamaoki M., Nishimura T., Takahashi N., Oda I., Tachimori Y., Arao T., Nishio K., Kitano S., Narumi K., Aoki K., Fujii S., Ochiai A., Yoshida T., Muto M., Yamada Y., Sasaki H.: Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy. *PLoS One*, 10(12), e0143804 (2015) 査読有り
- 33) Kano H., Okada K., Morimoto K., Bao W., Fukase K., Ito A., Okita Y.: Prediction of reversibility of intestinal mucosal damage after ischemia-reperfusion injury by plasma intestinal fatty acid-binding protein levels in pigs. *Perfusion*. 30, 617-625 (2015) 査読有り
- 34) Kato T., Mizuguchi N., Ito A.: Blood pressure, renal biochemical parameters and histopathology in an original rat model of essential hypertension (SHRSP/Kpo strain). *Biomed Res.* 36, 169-177 (2015) 査読有り
- 35) Kato T., Mizuguchi N., Ito A.: Characteristics of podocyte injury in malignant hypertensive nephropathy of rats (SHRSP/Kpo strain). *Biomed Res.* 36, 313-321 (2015) 査読有り
- 36) Kato T., Oka K., Nakamura T., Ito A.: Bronchioalveolar morphogenesis of human bronchial epithelial cells depending upon hepatocyte growth factor. *J Cell Mol Med.* 19, 2818-2826. (2015) 査読有り
- 37) Fujita M., Matsui T., Ito A.: Biomedical insights into cell adhesion and migration from a viewpoint of central nervous system tumor immunology. *Front Cell Dev Biol.* 10.3389/fcell.2015.00055. (2015) 査読有り
- 38) Takeda M., Sakai K., Terashima M., Kaneda H., Hayashi H., Tanaka K., Takahama T., Yoshida T., Iwasa T., Shimizu T., Nonagase Y., Kudo K., Tomida S., Mitsudomi T., Saigo K., Ito A., Nakagawa K., Nishio K.: Clinical application of amplicon-based next-generation sequencing to therapeutic decision-making in lung cancer. *Ann Oncol.* 26, 2477-2482. (2015) 査読有り
- 39) Yoneshige A., Hagiya M., Fujita M., Ito A.: Pathogenic actions of cell adhesion molecule 1 in pulmonary emphysema and atopic dermatitis. *Front Cell Dev Biol.* 10.3389/fcell.2015.00075. (2015) 査読有り

## 図 書

- 1) 岩城正宏ら: 医療薬学 VI 薬の生体内運命, 日本薬学会編, 東京化学同人, 195 ページ, 2015
- 2) 深尾亜喜良、藤原俊伸: 臨床免疫・アレルギー科, ヒトにおける microRNA が蛋白質合成を制御する機序の解明, 科学評論社, 64(3)、pp. 307-312、2015

- 3) 深尾亜喜良、藤原俊伸: 細胞工学「パラダイムシフトする翻訳制御研究」, microRNA 機構と RNA 結合タンパク質による翻訳制御, 学研メディカル秀潤社, 34(8)、pp. 767-771、2015
- 4) 西尾和人 リキッド・バイオブシー 腫瘍内科 16(6): 608-12, 2015.
- 5) 水上拓郎, 西尾和人 FGFR 阻害薬のバイオマーカー がん分子標的治療 13(3): 371-76, 2015.
- 6) 西尾和人, 坂井和子, 富樫庸介 【固形がんの分子標的薬-基礎研究から創薬・開発・臨床まで-】 がん分子標的治療の臨床 PI3K/mTOR シグナル系と分子標的治療 日本臨床 73(8): 1315-22, 2015.
- 7) 富樫庸介, 西尾和人 【固形がんの分子標的薬-基礎研究から創薬・開発・臨床まで-】 がん分子標的治療の臨床 キナーゼ阻害剤とその耐性化機構 日本臨床 73(8): 1323-29, 2015.
- 8) 西尾和人 【消化器癌の分子標的治療】 消化器がんのバイオマーカー 細胞 47(9): 442-45, 2015.
- 9) 富田秀太, 坂井和子, 西尾和人 バイオマーカー探索における bioinformatics の役割 がん分子標的治療 13(1): 113-18, 2015.
- 10) 西尾和人 用語解説 circulating DNA Cancer Board of the Breast 1(1): 67, 2015.
- 11) 富田秀太, 坂井和子, 西尾和人 ゲノム解析に基づく新しい分子標的治療】次世代型コンパニオン診断薬の創出を目指したゲノム解析 がん分子標的治療 12(4): 382-87, 2015.
- 12) 富樫庸介, 西尾和人 診断の進歩 シークエンス技術の発展と肺癌の driver oncogene Annual Review 呼吸器 2015: 133-40, 2015.